Latest research on Octreotide

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.

Octreotide dosage

Prednisone and Indomethacin are also considered to be effective in alleviating the clinical symptoms; therefore, Octreotide, at a dosage of 100 mg daily, combined with 20 mg Prednisone daily were administered to the patient in this study to control the symptom of diarrhea and arrest the liver metastasis. [source, 2016]
The combined application of corticosteroids with Octreotide may reduce the required dosage of Octreotide, avoid the side-effects and ease the financial burden of the patient. [source, 2016]
EAS can be diagnosed biochemically by demonstrating non-suppressibility with a high dose DST; however, it must be borne in mind that the sensitivity and specificity of this test is not 100% (4), and hence, if imaging with CT or MRI, and functional studies such as Octreotide scintigraphy do not demonstrate a tumour, the diagnosis of EAS should be questioned and Cushing's disease should be reconsidered. [source, 2015]
In few cases, mild carcinoid crisis is seen and can be sufficiently treated with small doses of Octreotide (e.g. 100 μg iv). [source, 2015]
Octreotide was started S/cly at a dose of 5 µg/kg/d 8 hrly with doses being gradually increased to 30 µg/kg/d 6 hrly. [source, 2015]
Worsening of symptoms as described by the patient or the need for higher doses of Octreotide to control symptoms were considered progression of disease. [source, 2015]
In addition, any increase in Octreotide dosage or report of new or worsening symptoms, no matter how minor, was interpreted as a sign of progressive disease. [source, 2015]
One week after dose escalation of Octreotide LAR, he was readmitted following an unconscious hypoglycaemic collapse. [source, 2015]
Predicting response to somatostatin analogues can be challenging and neither Octreotide test doses nor Indium-111 scintigraphy may be helpful in some patients (7). [source, 2015]
Hence, blood glucose levels should always be monitored closely when initiating therapy with Octreotide or following dose escalation in all patients with malignant insulinoma. [source, 2015]